Sign in

You're signed outSign in or to get full access.

Alexander Herzick

Director at Alpha Teknova
Board

About Alexander Herzick

Alexander Herzick (age 44 as of April 22, 2025) is a Class I director of Alpha Teknova, Inc. (TKNO), serving since January 2019; he is a Partner at Telegraph Hill Partners (“THP”) since June 2018, with prior roles at BlueMountain Capital Management and Bank of America Securities, and holds a BA in Economics from Duke University and an MBA with honors from Kellogg School of Management . He is standing for re‑election to a term ending at the 2028 annual meeting . TKNO is a “controlled company” under Nasdaq rules due to THP’s majority ownership .

Past Roles

OrganizationRoleTenureCommittees/Impact
Bank of America SecuritiesAnalyst, Investment BankingJun 2003 – Jun 2005Early finance training
BlueMountain Capital Management (now Assured Investment Management)Portfolio ManagerJun 2005 – Jun 2007Buy‑side portfolio management experience
Telegraph Hill Partners (THP)PartnerJun 2018 – PresentGrowth equity in life sciences; partner at THPMC (manager of THP funds)

External Roles

OrganizationRoleTenureNotes
Carterra, Inc.Director (represents THP)CurrentPrivate portfolio company
Argonaut Manufacturing Services, Inc.Director (represents THP)CurrentPrivate portfolio company
Cell Microsystems, Inc.Director (represents THP)CurrentPrivate portfolio company
Excellos, Inc.Director (represents THP)CurrentPrivate portfolio company
Dynex Technologies, Inc.Director (represents THP)CurrentPrivate portfolio company

No public company directorships disclosed for Herzick outside TKNO .

Board Governance

  • Board class and term: Class I; term expires at 2025 annual meeting; nominated for 2028 term .
  • Committee assignments: Herzick is not listed as a member of the Audit, Compensation, or Nominating & Corporate Governance Committees; (footnote indicators absent next to his name) .
  • Independence: Not independent under Nasdaq rules due to employment with Telegraph Hill Management Company LLC (“THPMC”), the corporate manager of THP .
  • Controlled company: TKNO utilizes controlled company exemptions (e.g., Compensation and Nominating committees not entirely independent) .
  • Attendance: In FY2024, the board held 9 meetings and acted by written consent twice; each director attended at least 75% of board and applicable committee meetings; only one director attended the 2024 annual meeting .

Fixed Compensation

YearAnnual Board Retainer ($)Committee Member Fees ($)Committee Chair Fees ($)Meeting Fees ($)Notes
2024Non‑employee, non‑independent directors did not receive retainers in FY2024
2023No director fees recorded for Herzick in FY2023 table

Policy reference (context for independent directors):

  • Board retainer $40,000; Committee member: Audit $10,000, Compensation $7,500, Nominating $5,000; Chair: Audit $20,000, Compensation $15,000, Nominating $10,000 .
  • Compensation caps: ≤$750,000 per year; ≤$1,000,000 in first‑year appointment .

Performance Compensation

YearRSUs Granted (#)Option Awards (Grant-Date FV $)Vesting TermsPerformance Metrics
2024N/A (no awards) None disclosed for directors; RSUs vest 1 year when granted to independent directors
2023N/A (no awards) None disclosed for directors

Context: Annual RSU grants for independent directors targeted at 0.10% of shares outstanding (modified to fixed 20,000 shares for FY2024); initial option grants for new independent directors at 0.20% of shares outstanding; RSUs vest after one year; options vest 1/3 at year 1, then monthly over 24 months .

Other Directorships & Interlocks

Person/EntityRelationshipGovernance Relevance
Entities affiliated with THP70.6% of common stock outstanding (37,717,565 shares) as of Apr 22, 2025 Controlling shareholder; TKNO classified as “controlled company”
Paul Grossman; J. Matthew MackowskiTKNO directors; partners/managers at THPMC Interlocks with Herzick via THP/THPMC; not independent
AONCompensation consultant engagement in 2025 Peer group and director compensation recommendations reviewed by committee

Expertise & Qualifications

  • Investment and growth equity expertise in healthcare/life sciences; transactional experience (debt/equity/M&A) .
  • Education: BA Economics (Duke), MBA with honors (Kellogg) .
  • Industry exposure across life science products and strategy/business development per board skills matrix .

Equity Ownership

HolderShares Beneficially Owned% of OutstandingNotes
Alexander HerzickDisclaims beneficial ownership of THP‑held shares; may be deemed beneficial owner via THPMC roles
Entities affiliated with THP37,717,565 70.6% THP IV LP, THP IV LLC, THP V LP, THP V LLC aggregated; shared voting/dispositive power

Shares outstanding base: 53,440,810 as of April 22, 2025 .

Governance Assessment

  • Independence: Non‑independent director tied to controlling shareholder (THP/THPMC), alongside two other non‑independent THP partners on the board—elevated conflict risk and reduced minority shareholder influence .
  • Committees: Herzick holds no committee seats; Compensation and Nominating committees include non‑independent directors under controlled company exemptions, potentially weakening independent oversight of pay and nominations .
  • Pay alignment: Herzick received no director cash or equity compensation in 2023–2024; while this avoids direct pay conflicts, his lack of direct share ownership diminishes personal “skin in the game,” with influence exerted through THP’s majority stake rather than individual holdings .
  • Attendance: Board‑level attendance met at least 75% in FY2024; annual meeting attendance was limited (one director), a modest engagement signal, though Herzick’s individual annual meeting attendance is not disclosed .

Red Flags

  • Controlled company governance with three THP‑affiliated, non‑independent directors (including Herzick) and use of exemptions from fully independent committees .
  • No direct beneficial ownership by Herzick; reliance on THP’s stake may misalign personal incentives with minority shareholders .
  • Charter provisions granting THP enhanced influence (e.g., removal/meeting mechanics tied to THP Trigger Event) and anti‑takeover effects, potentially entrenching control .

Note: Director‑specific performance metrics, severance/change‑of‑control terms, hedging/pledging, related‑party transactions involving Herzick personally, and Form 4 insider trades are not disclosed in the cited filings.